共 151 条
[1]
Bae JMJK(2002)Annual report of the Korea Central Cancer REgistry Program 2000: based on registered data from 131 hospitals Cancer Res Treat 34 77-83
[2]
Park JG(2002)Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial Jpn J Clin Oncol 32 248-254
[3]
Bang YJ(2005)ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of gastric cancer Ann Oncol 16 i22-i23
[4]
Kang WK(1997)Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163-168
[5]
Kang YK(2008)Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group Br J Cancer 98 542-546
[6]
Kim HC(1993)A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813-3818
[7]
Jacques C(2008)S–1 plus cisplatin versus S–1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221
[8]
Zuber E(1993)Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37-41
[9]
Daglish B(2007)Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer Cancer Chemother Pharmacol 59 17-21
[10]
Boudraa Y(1995)Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587-591